CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 21 enrolled
Drug / intervention
Acetylsalicylic acid +1 moredrug
Likely dose
Acetylsalicylic acid 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03341117
NCT03341117Phase 3Completed

Acetylsalicylic Acid Administered in Patients With Type 2 Diabetes Mellitus and Its Effect on the Antioxidant Enzyme System

Centro Universitario de Ciencias de la Salud, Mexico·interventional·Posted Nov 14, 2017·Updated Nov 14, 2017

In Brief

A Phase 3 clinical trial evaluating Acetylsalicylic acid and Calcined magnesia for Diabetes Mellitus, Type 2 and Antioxidant Enzyme System. Completed, enrolled 21 participants.

Detailed Summary

OBJETIVE To assess the effect of acetylsalicylic acid on antioxidant enzymatic system in patients with type 2 diabetes

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 14, 2017
Enrollment StartDec 2, 2014
Primary CompletionDec 2, 2015
Study CompletionDec 2, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 8.6 years ago

Interventions

Acetylsalicylic aciddrug

Acetylsalicylic acid 300 mg per capsule

Calcined magnesiadrug

Calcined magnesia 300 mg per capsule